首页> 美国卫生研究院文献>PLoS Clinical Trials >Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
【2h】

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

机译:乳酸菌和双歧杆菌的口服益生菌组合在艰难梭菌感染的抗生素治疗过程中改变了胃肠道菌群

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
机译:抗生素引起的胃肠道微生物组扰动是艰难梭菌感染(CDI)的主要危险因素。通常建议使用益生菌来减轻CDI症状。然而,仅有有限的证据显示益生菌对CDI有功效。在这里,我们研究了益生菌治疗与CDI腹泻持续时间明显减少有关的研究人群中胃肠道微生物群的变化。将接受标准CDI护理的标准抗生素治疗的患者随机分组进行4周的益生菌治疗或安慰剂治疗。益生菌治疗包括每日多株胶囊(1.7 x 10 << sup> 10 个CFU。收集粪便并使用16S rRNA测序进行分析。微生物组分析显示治疗和时间点之间明显的分类学差异。与对照相比,施用益生菌的受试者在第8周的Verrucomicrobiaceae减少。在益生菌治疗的受试者中,杀菌剂在0至4周之间显着减少。在安慰剂组中,Ruminococcus(家族的Lachnospiraceae)在第8周时比在第4周时含量更高,而在益生菌组中,在第8周时比第0周时含量更高。与这些结果相似,以前的研究已经将这些分类群与益生菌的使用和CDI症状的缓解相关联。微生物群落功能的组成预测显示,安慰剂组的受试者的微生物群富含铁复合物转运系统,而经益生菌治疗的受试者的微生物群富含抗生素转运系统。结果表明,使用益生菌可能会影响面对CDI的微生物组功能。但是,必须使用更高分辨率的更敏感方法来更好地阐明与这些更改相关的角色。需要继续研究以更好地了解益生菌对微生物组结构和功能的影响以及对CDI的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号